Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SURV-SEP
- 24 May 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 Planned primary completion date changed from 1 Jan 2023 to 1 Aug 2019.
- 28 Sep 2016 New trial record